2Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β- lactamase gene, blaNDM- 1, and a novel e- rythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India[J]. An- timicrob Agents Chemother, 2009,53 (12) : 5046- 5054.
3Dai W, Sun S, Yang P, et al. Characterization of carbapenemas- es, extended spectrum β- lactamases and molecular epidemiol- ogy of- carbapenem- non- susceptible Enterobacter cloacae in a Chinese hospital in Chongging[J]. Infect Genet Evol,2013 (14):1-7.
6Reinert RR,Low DE,Rossi F. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim,Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline[J].{H}Journal of Antimicrobial Chemotherapy,2007,(5):1018-1029.
7Postier RG,Green SL,Klein SR. Results of a multicenter,randomized,open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients[J].{H}Clinical Therapeutice,2004,(5):704714.
8Sacchidanand S,Penn RL,Embil JM. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam inpatients with complicated skin and skin structure infections:Results from a phase 3,randomized,double-blind trial[J].{H}International Journal of Infectious Diseases,2005,(5):251-261.
9Bergallo C,Jasovich A,Teglia O. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia:results from a double-blind randomized phase 3 comparison study with levofloxacin[J].{H}Diagnostic Microbiology and Infectious Disease,2009,(1):52-61.
